| Market Cap | 24.0B |
| P/E Ratio | - |
| P/B Ratio | - |
| EPS | 1.30 |
| Dividend Yield | - |
| D/E Ratio | 0.08 |
| Current Ratio | 9.60 |
| Market Segment | SME |
| Currency | CNY |
Business Overview
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and distribution of medicine for ophthalmic, neuropsychiatric and other applications in China. It also develops a pipeline of clinical and pre-clinical programs for ophthalmology, CNS, oncology, and common disease. The company was founded in 1996 and is based in Chengdu, China.
Key Financial Metrics
Profitability
Returns & Efficiency
Financial Health
| Industry | Pharmaceutical Manufacturing |
| Market Segment | SME |
| Currency | CNY |
| Fiscal Year | 2024 |
Stock Chart
Full charting with technical indicators, candlestick, line charts, and more.
Company Profile
| Company Name | 康弘药业 |
| Ticker | 002773 |
| Exchange | SZSE |
| Sector | CSRC Classification |
| Industry | Pharmaceutical Manufacturing |
| Market Segment | SME |
| Fiscal Year | 2024 |
| Currency | CNY |
| Market Cap | 24.0B |
| Revenue | 4.5B |
| Net Income | 1.2B |
| P/E Ratio | - |
| EPS | 1.30 |
| Net Margin | 26.4% |
| ROE | 13.6% |
| Dividend Yield | - |
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and distribution of medicine for ophthalmic, neuropsychiatric and other applications in China. It also develops a pipeline of clinical and pre-clinical programs for ophthalmology, CNS, oncology, and common disease. The company was founded in 1996 and is based in Chengdu, China.